HIGHLIGHTS
- who: Malcolm S. Duthie and colleagues from the HDT Bio, Eastlake Ave E, Seattle, WA, USA SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), University Center have published the Article: Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs, in the Journal: Pathogens 2022, 11, x FOR PEER REVIEW of /2022/
- what: __SECTION__ 5. Conclusions.
SUMMARY
Most infections remain asymptomatic (e_g, 90% of humans infected with L donovani do not advance to symptoms) with a key element for parasite containment being an effective antigen-specific . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.